<aside> 💡

Enantios is revolutionizing pharmaceutical molecular analysis with breakthrough ROA technology - delivering 100x faster structural characterization that's impossible with existing methods.

✓ 2 Top-10 Pharma customers | ✓ $200K revenue 2025 (3x growth) | ✓ $800K pipeline | ✓ Raising Series A $6-7M Q2 2026

</aside>

YTDown.com_YouTube_ETH-Zurich-spin-off-Enantios_Media_lMVQetjCFbg_001_1080p.mp4

🎯 The Investment Opportunity

<aside> 🚀

Investment Round: $6-7M USD (CHF 5-6M)

Target Close: Q2 2026

</aside>

Why Invest Now?

✓ Proven Market Traction

• 3 Top-10 pharma customers actively using our technology
• $200K revenue 2025 (3x growth from 2024's $60K)
• $800K+ in pending quotations
• Strong LOIs from Bristol Myers Squibb, Eli Lilly, GalChimia, EuroFins

✓ Massive Market Opportunity

• Discovery & Development: $4B global market
• QA/QC Manufacturing: $24B global market
• Switzerland alone: $154M addressable market
• Growing demand driven by complex molecules & biologics

✓ De-risked Technology

• Gen 1 instrument deployed and generating revenue
• Peer-reviewed publications (Journal of Physical Chemistry, ACS Photonics)